App-Quantinova.ai

Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study

Tndel Camilla - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Fabry disease

Agalsidase alfa

Treatment for CKD: A Systematic Literature Review and Population Comparison

Garcia Sanchez Juan Jose - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

The Impact of Decline in Renal Function on the Clinical and Economic Burden of CKD: An Application of the DAPA-CKD Cost-Effectiveness Model

McEwan Philip - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

Development of a CKD Model in Cynomolgus Monkeys and Its Application to Test Zampilimab, a Monoclonal Antibody (mAb) Specific for Human Transglutaminase 2 (TG2)

Huang Linghong - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Kidney fibrosis

N/A

Human Induced Pluripotent Stem Cell-Derived Kidney Micro-Organoids for High Throughput Disease Modeling in Drug Discovery

Kumar Santhosh V - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Angiotensin II

Lipid Metabolic Profiling of Ex Vivo Isolated Glomeruli as a Screening Platform for Modelling Glomerular Metabolic Dysfunction During Renal Disease

Romoli Simone - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal disease

Adriamycin injection

Single-Nucleus RNA Sequencing Identifies New Classes of Renal Proximal Tubular Epithelial Cell in Kidney Fibrosis

Lu Yuehan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Kidney fibrosis

Aristolochic acid

Artificial Intelligence-Driven Target Identification in CKD

Kumar Chanchal - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Renal Involvement in Coronavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis

Chan Kam wa - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Coronavirus disease

N/A

COVID-19 AKI: Risk Factors and Markers of Disease from a Large UK Cohort

Phillips Thomas - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Acute Peritoneal Dialysis with Percutaneous Catheter Insertion for COVID-19-Associated AKI in Intensive Care: Experience from a UK Tertiary Centre

Braide-Azikiwe DandisonbaBamidele Chinwe - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Can the AKI Alert Staging Tool Help Manage Patients Admitted During the COVID Pandemic?

Mohidin Barian - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Is AKI in COVID-19 Patients Associated with Increased Mortality?

Muthuppalaniappan Vasantha�M. - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Single-Center Experience of AKI in COVID-19-Infected Patients in West Kent Hospital, United Kingdom

James Matthew - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Clinical Symptoms in 44 Hemodialysis Patients Who Survived and Recovered from a Confirmed SARS-CoV-2 Infection and COVID-19 in Relation to Age and Hospitalization: An International Experience

Ruiz Mauricio - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Ferritin and Lymphopaenia as Markers of COVID-19 in a Haemodialysis Population

Makanjuola David - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Rates of Asymptomatic Carriage and Antibody Positivity for SARS-CoV-2 in a Large Haemodialysis Cohort

Mccafferty Kieran - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Clinical Characteristics, Management, and Outcomes in COVID-19-Positive Dialysis Patients from Three London Renal Centres, United Kingdom

Kular Dalvir - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Methemoglobinemia and AKI in Patients with COVID-19: Don’t Forget G6PD Deficiency

Nafees Samraiz - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Severe COVID-19 pneumonia

Hydroxychloroquine

RAAS Inhibition, Mortality, and Severity in COVID-19 Patients: A Systematic Review and Meta-Analysis

Ali Hatem - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Filters

45280 Abstracts